Daniele Alberti

Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Giuseppe Maschio, Daniele Alberti, G. Janin et al. · New England Journal of Medicine · 1996 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +14

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Giovanni Martinelli, Gianantonio Rosti et al. · Journal of Clinical Oncology · 2005 · 372 citations · Full text

Medicine, Hematology, Pharmacology +14

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

Eric Nisbet‐Brown, Nancy F. Olivieri, Patricia J. Giardina et al. · The Lancet · 2003 · 330 citations

Medicine, Hematology, Pharmacology +12

A randomised comparison of deferasirox<i>versus</i>deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Elliott Vichinsky, Onyinye Onyekwere, John B. Porter et al. · British Journal of Haematology · 2006 · 271 citations · Full text

Medicine, Hematology, Pharmacology +17

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17